Biohealth Innovation - 364th Edition

BioHealth Innovation

If you are having trouble viewing this email, please click here

July 30, 2019

FOUNDING MEMBER OF

MaxCyte Founder, President and CEO Doug Doerfler joins Rich Bendis on BioTalk

MaxCyte Founder, President and CEO Doug Doerfler joins BioTalk to discuss his history and the growth of the company. He also shares advice for entrepreneurs

Mr. Doerfler has more than 35 years of experience in the discovery, development, commercialization and international financing of biotechnology products and companies. He was a founder of MaxCyte in July 1998. Previously, Mr. Doerfler was President, CEO and a Director of Immunicon Corporation, a cell-based therapy and diagnostics company. He also held various executive positions with Life Technologies, Inc.(now Thermo Fisher Scientific). Mr. Doerfler plays an active role as a life sciences industry advocate, serving as Chair Emeritus of the MTC and on the executive committee of BIO.

Listen now on iTunes (https://apple.co/318CzZv), Google (http://bit.ly/30WiQfg), and TuneIn (http://bit.ly/2LPtYab).

Children's National 7th Annual Pediatric Device Innovation Symposium features $150K NICU pitch competition and explores clinical trial process

The Sheikh Zayed Institute for Pediatric Surgical Innovation at Children's National Health System announces its 7th Annual Pediatric Device Innovation Symposium is slated for Sunday, Sept. 22 in Boston, Mass., featuring a $150K medical device competition focused on innovations for neonatal and NICU care. Following the theme "Pediatric Device Clinical Trials: Forging a Better Path," this year's symposium explores the pediatric device clinical trial process, including progress insights, current challenges and potential solutions.

Emmes Honored for Workplace Excellence | Emmes

Emmes today announced that it has received a Workplace Excellence Seal of Approval from Alliance for Workplace Excellence (AWE). This is the fifth consecutive year the company has received the AWE Workplace Excellence award.

gel-e Inc., announces Breakthrough Status Designation from the U.S. Food and Drug Administration (FDA) for its first internal-use flowable device

gel-e is developing a line of advanced hemostatic and wound treatment products that address unmet needs from the operating room to the backyard. Following previous clearances for topical and external use of its platform technology (see http://www.gel-e.co/news.html), the Company is now expanding its label to include use for internal and surgical applications. The first product, now on an accelerated path as a Breakthrough Device, is an expanding injectable hemostat, Life Foam™. Life Foam can rapidly provide temporary control of bleeding from non-compressible abdominal wounds that are not amenable to tourniquet application in trauma and battlefield conditions. As the tradename suggests, this product is designed to save the lives of those injured in battle, or that are the victims of traumatic accidents or even terrorist attacks.

BrainScope Surpasses Primary Endpoints in Multi-Year Department of Defense-Funded Validation Study for New Concussion Assessment Capability — BrainScope

BrainScope announced today that it has successfully completed a nearly five year, $9.9 million U.S. Department of Defense research contract supporting the development and validation of an objective marker of the presence and severity of concussion. In a large blinded validation study, the system demonstrated its ability to help clinicians assess concussion at the time of injury, reflect severity of injury, and aid in their assessment of readiness to return to activity. BrainScope extended the work performed under this Department of Defense contract to include adolescents funded through private investment from BrainScope and a second award from the NFL-GE Head Health Challenge I.

George Mason University breast cancer treatment patent licensed by Targeted Pharmaceuticals | EurekAlert! Science News

A patent granted to George Mason University Research Foundation Inc., which describes a novel treatment method for pre-invasive breast cancer, has been exclusively licensed to Targeted Pharmaceuticals LLC, a clinical-stage biopharmaceutical company focused on utilizing cannabinoids for the treatment of oncology and central nervous system disorders.

Johns Hopkins University Wins Grant to Grow Regional Digital Health Resources and Companies

The U.S. Economic Development Administration awarded more than $600,000 to a division of Johns Hopkins University on Tuesday to increase economic development in the region’s digital health field.

MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform

MaxCyte, the global clinical-stage cell-based therapies and life sciences company, announced today that it has appointed Dr. Dhana Chinnasamy, a 20+-year expert in the research and translation of gene and immunotherapies, as its Vice President, Non-Clinical and Translational Studies. In her new role, Dr. Chinnasamy will oversee all non-clinical and translational activities for MaxCyte's CARMA platform working closely with the clinical, regulatory, manufacturing, and business development teams in support of MaxCyte's clinical-stage therapeutic development.

Biotech Startups On the Rise in Frederick, Maryland · BioBuzz

Frederick, Maryland continues to be a hotbed for biotech and a destination of choice for many new startups. The last few years have seen one-time startups like RoosterBio, Inc., BioFactura, Inc. and Akonni Biosystems thrive and grow within the Frederick life science support ecosystem.

How to Build a Leadership Team that Attracts Venture Capital · BioBuzz

If you attended any of the events, conferences and panel discussions in the BioHealth Capital Region this year you probably would have picked up on a consistent theme. Whether it was at the ISPE Chesapeake Bay Area Chapter’s MAST Showcase, the BioHealth Capital Region Forum held at AstraZeneca in April or the more recent NCI Tech Transfer Showcase, talent and capital were hot button topics discussed intensely during the sessions, over lunch and while networking at each event.

Some shifts in venture capital financing of biopharma companies appear underway

Venture capital fundraising this year by biopharma startups is on course to fall behind last year, though it will be above the figure for 2017. But the biggest story may be where that funding is going.

AUTM - Egypt Tech Transfer Partnership and Information Exchange

AUTM - #Egypt tech transfer partnership and information exchange co-sponsored by the USDA continues this week with stops this week at #Maryland TEDCO and BioHealth Innovation, Inc. in the BioHealth Capital Region

College of Science – George Mason University Patent with Applications to Breast Cancer Treatment Licensed by Targeted Pharmaceuticals, a Cannabinoid-Based Drug Discovery Company

Baltimore area needs a regional economic development strategy - Baltimore Sun

In the last five to 10 years, it would seem as though Baltimore is finally emerging (at least economically) — from its slow, multi-decade decline. But if you’re a resident of one of the city’s poorer neighborhoods, you might not know it.

Red Wine Compound for Treating Depression and Anxiety?

A nice, relaxing glass of Bordeaux or Cabernet might easily seem like the perfect treatment for an anxious or slightly depressed state. Though, the alcohol might lead one down a slippery path rather quickly. Instead, investigators at the University of Buffalo (UB) and Xuzhou Medical University in China have decided to focus their attention on the widely studied plant compound—found in considerably higher levels in red wine than most other plants—called resveratrol. This phenolic compound has been studied for several decades, in connection with reduced incidence of cardiovascular disease and for the treatment of cancer, with mixed results. Yet now, researchers found new evidence of resveratrol displaying anti-stress effects by blocking the expression of an enzyme related to the control of stress in the brain.

‘Browning’ white fat cells opens new avenue to obesity prevention – Horizon Magazine Blog

Scientists are getting closer to understanding how to turn the body’s energy-storing white fat cells into energy-burning beige fat cells, opening up hopes that fat deposits could one day be deliberately manipulated to prevent obesity and related health conditions.

New Brunswick's Venn Innovation receives $475,000 from federal government | BetaKit

Venn Innovation, a non-profit Moncton-based incubator established to connect New Brunswick’s tech ecosystem, has received approximately $475,000 from the federal government in the form of a grant.